Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases
Niraparib as maintenance therapy in a patient with ovarian cancer and brain metastases
复制标题
DOI：
10.1136/bcr-2019-230738
复制
发表时间：
2019-08-01
期刊：
影响因子：
0.9
通讯作者：
Yiannakis, Dennis
中科院分区：
文献类型：
--
作者：
Gray, Simon;Khor, Xiao Ying;Yiannakis, Dennis
卵巢癌是发达国家第二常见的妇科恶性肿瘤。70%的患者在减瘤手术和一线化疗后的前3年内复发。Niraparib是一种多聚腺苷二磷酸核糖聚合酶抑制剂，在乳腺癌易感基因（BRCA）存在突变的情况下使用合成致死性概念，目前推荐作为铂敏感性卵巢癌复发患者的维持治疗。它已被证明可以增加无进展生存期。我们介绍了一例68岁的高级别浆液性卵巢癌脑转移女性患者，在二线化疗后使用Niraparib作为维持治疗，17个月以上未发生疾病进展。
Ovarian cancer is the second the most common gynaecological malignancy in developed countries. 70% of patients relapse in the first 3 years following debulking surgery and first-line chemotherapy. Niraparib is a poly adenosine diphosphate ribose polymerase inhibitor which uses the concept of synthetic lethality in the presence of a mutation in the breast cancer susceptibility gene (BRCA), and is now recommended as maintenance treatment in patients with platinum-sensitive relapse of ovarian cancer. It has been shown to increase progression-free survival. We present a case of a 68-year-old woman with brain metastases from high-grade serous ovarian cancer who has remained free of disease progression for longer than 17 months with niraparib use as maintenance treatment after second-line chemotherapy.